Tejara Capital Ltd Invests $4.86 Million in ARS Pharmaceuticals, Inc. $SPRY

Posted by Francis Steltz on Aug 21st, 2026

Tejara Capital Ltd bought a new stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) in the 2nd quarter, HoldingsChannel reports. The firm bought 607,039 shares of the company’s stock, valued at approximately $4,862,000. ARS Pharmaceuticals accounts for about 2.0% of Tejara Capital Ltd’s holdings, making the stock its 16th largest position.

A number of other large investors have also recently added to or reduced their stakes in SPRY. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of ARS Pharmaceuticals by 25.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock valued at $56,000 after acquiring an additional 982 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of ARS Pharmaceuticals by 3.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,994 shares of the company’s stock worth $596,000 after purchasing an additional 1,234 shares during the period. ProShare Advisors LLC lifted its holdings in shares of ARS Pharmaceuticals by 11.3% during the fourth quarter. ProShare Advisors LLC now owns 15,139 shares of the company’s stock valued at $176,000 after purchasing an additional 1,532 shares during the last quarter. FAS Wealth Partners Inc. lifted its holdings in shares of ARS Pharmaceuticals by 0.9% during the fourth quarter. FAS Wealth Partners Inc. now owns 202,407 shares of the company’s stock valued at $2,358,000 after purchasing an additional 1,787 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its position in shares of ARS Pharmaceuticals by 52.8% in the 2nd quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock valued at $91,000 after purchasing an additional 1,803 shares during the period. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals Stock Down 13.6%

NASDAQ:SPRY opened at $5.51 on Friday. The firm has a market capitalization of $547.97 million, a price-to-earnings ratio of -2.53 and a beta of 0.98. ARS Pharmaceuticals, Inc. has a 1-year low of $4.91 and a 1-year high of $15.09. The company has a current ratio of 3.48, a quick ratio of 3.28 and a debt-to-equity ratio of 13.72. The business’s fifty day moving average price is $7.32 and its 200 day moving average price is $8.18.

ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.15). The business had revenue of $33.66 million for the quarter, compared to analyst estimates of $31.32 million. ARS Pharmaceuticals had a negative return on equity of 256.67% and a negative net margin of 184.24%. On average, sell-side analysts forecast that ARS Pharmaceuticals, Inc. will post -1.9 earnings per share for the current fiscal year.

Insider Activity at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, insider Alexander A. Fitzpatrick sold 3,355 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $10.00, for a total value of $33,550.00. Following the completion of the sale, the insider owned 90,910 shares in the company, valued at $909,100. This represents a 3.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Karas sold 25,000 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Following the completion of the sale, the insider owned 12,176 shares of the company’s stock, valued at approximately $121,760. The trade was a 67.25% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 33.80% of the company’s stock.

Key Headlines Impacting ARS Pharmaceuticals

Here are the key news stories impacting ARS Pharmaceuticals this week:

Positive Sentiment: Wall Street analysts’ average price target implies approximately 297% potential upside from recent levels. Zacks also noted a favorable trend in earnings-estimate revisions, though it cautioned that price targets are an imperfect indicator. Can ARS Pharmaceuticals Climb to Reach Analysts’ Expectations?
Neutral Sentiment: ARS Pharma’s second-quarter 2026 earnings call transcript was published, giving investors additional detail on the company’s financial results, commercial execution and outlook. The supplied report does not identify a specific new catalyst or guidance change. ARS Pharma Q2 2026 Earnings Call Transcript
Negative Sentiment: Multiple law firms announced or promoted a securities class action against ARS Pharmaceuticals and certain officers. The lawsuit alleges that the company’s statements about a July 1, 2026 CVS Caremark formulary effective date failed to adequately warn that expanded coverage for neffy could be delayed until January 2027. The alleged disclosure issue reportedly preceded a single-day 23.9% share decline and a loss of approximately $2.52 per share for affected investors. The October 5, 2026 deadline to seek lead-plaintiff status adds continued legal and reputational overhang. These are allegations, not findings of wrongdoing. SPRY Investor Alert and Securities Class Action Notice

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on SPRY shares. Weiss Ratings cut ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. Cantor Fitzgerald raised their target price on shares of ARS Pharmaceuticals from $12.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 28th. Leerink Partners cut their price target on shares of ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Thursday, June 25th. Finally, Wall Street Zen upgraded shares of ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ARS Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $28.20.

Get Our Latest Analysis on ARS Pharmaceuticals

ARS Pharmaceuticals Company Profile

(Free Report)

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.